enVVeno Medical Stock Set to Reverse Split on Tuesday, January 20th (NASDAQ:NVNO)

enVVeno Medical Corporation (NASDAQ:NVNO) shares are going to reverse split on the morning of Tuesday, January 20th. The 1-35 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th.

enVVeno Medical Price Performance

NASDAQ NVNO opened at $0.31 on Friday. enVVeno Medical has a one year low of $0.30 and a one year high of $5.62. The firm has a market cap of $6.34 million, a P/E ratio of -0.29 and a beta of 1.04. The stock’s 50-day moving average is $0.38 and its 200-day moving average is $1.64.

enVVeno Medical (NASDAQ:NVNO) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.23) earnings per share for the quarter. Equities analysts anticipate that enVVeno Medical will post -1.32 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of enVVeno Medical in a research report on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Reduce”.

Hedge Funds Weigh In On enVVeno Medical

A number of large investors have recently bought and sold shares of NVNO. Kingdon Capital Management L.L.C. grew its stake in shares of enVVeno Medical by 58.2% during the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,359,261 shares of the company’s stock worth $1,232,000 after acquiring an additional 500,000 shares in the last quarter. CM Management LLC acquired a new position in enVVeno Medical during the third quarter worth $544,000. Perceptive Advisors LLC acquired a new position in enVVeno Medical during the second quarter worth $5,127,000. Jane Street Group LLC bought a new position in enVVeno Medical in the second quarter valued at $51,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in enVVeno Medical in the 2nd quarter valued at $798,000. Institutional investors and hedge funds own 34.71% of the company’s stock.

About enVVeno Medical

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.